Evidence map›Paper›PMID 40893367›Full record

ArticleMaterials today. Bio2025

Theranostic porphyrin nanoparticles identify atherosclerosis via multimodal imaging and elicit atheroprotective effects.

Victoria A Nankivell, Lauren Sandeman, Liam Stretton, Achini K Vidanapathirana, Maneesha A Rajora, Juan Chen, William Tieu, Hanyi Weng, Maaike Kockx, Leonard Kritharides and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026
    Review
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Victoria A NankivellVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Lauren SandemanVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Liam StrettonVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Achini K VidanapathiranaVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Maneesha A RajoraPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 1L7, Canada.
Juan ChenPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 1L7, Canada.
William TieuVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Hanyi WengPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 1L7, Canada.
Maaike KockxANZAC Research Institute, Concord Repatriation General Hospital, Sydney Local Health District and University of Sydney, Australia.
Leonard KritharidesANZAC Research Institute, Concord Repatriation General Hospital, Sydney Local Health District and University of Sydney, Australia.
Peter J PsaltisVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Joanne T M TanVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.
Yung-Chih ChenAtherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Karlheinz PeterAtherothrombosis and Vascular Biology, Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Gang ZhengPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, M5G 1L7, Canada.
Christina A BursillVascular Research Centre, Lifelong Health Theme, South Australian Health and Medical Research Institute, Adelaide, South Australia, 5000, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Porphyrin-lipid nanoparticles (Por-NPs) have unrealized potential for atherosclerosis. Por-NPs incorporate porphyrin-lipid which permits fluorescence imaging and chelates Copper-64 ( Results: Conclusions: Por-NPs detect plaques using multiple imaging modalities and exhibit atheroprotective effects, presenting as novel nanoscale theranostics for atherosclerosis.

Indexed as

Anti-inflammatoryImaging atherosclerosisLipid-based nanoparticlesMultimodal imagingPorphyrin-lipid

Identifiers

PMID40893367
PMCPMC12398886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.